Keywords: USA, FDA, AstraZeneca, Crestor, Cholesterol lowering

US FDA panel gives majority support for broader indication on AstraZeneca’s Crestor

Article | 16 December 2009

Print This

As was widely expected following informal comments from a reviewer a few days ago (The Pharma Letter December 14), the US ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in